BOLT — Bolt Biotherapeutics
NASDAQ · Healthcare · Biotechnology
$4.07
+$0.09 (+2.26%)
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on NASDAQ. It is led by William P. Quinn, based in 900 Chesapeake Drive, Redwood City, CA, United States, 94063, with about 52 employees. Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Latest reported BOLT revenue for 2025-09-30 was $2.2M. Net income was -$26.7M. Revenue was up 20.2% from 2025-06-30 to 2025-09-30. BOLT currently screens at market cap $11.3M.
Use this BOLT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BOLT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BOLT SEC filings page. Lician reads the product cache first so this HTML stays unique to Bolt Biotherapeutics even when a live quote feed is slow.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
BOLT Key Statistics
Market Cap
$11.33M
Volume
2,380
Previous Close
$3.74
Day Range
$3.74 – $3.85
EPS
-$1.65
Revenue
$7.69M
Net Income
-$63.12M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-2.4%
Profit Margin
-820.8%
Employees
52
BOLT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $7.69M | $7.88M | $5.73M | $1.26M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$63.12M | -$69.20M | -$88.10M | -$98.59M |
| EPS (Diluted) | -$1.65 | -$1.83 | -$2.36 | -$2.97 |
Total Assets
$99.63M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$7.21M
Operating Cash Flow
-$61.29M
Free Cash Flow
$0.00
Bolt Biotherapeutics Company Information
- CEO, CFO, President, Secretary & Director
- William P. Quinn
- Headquarters
- 900 Chesapeake Drive, Redwood City, CA, United States, 94063
- Website
- www.boltbio.com
- Phone
- 650 665 9295
- IPO / Founded
- 2021-02-05
- Sector
- Healthcare
- Industry
- Biotechnology